IFM 2014-01: IxPd in Relapsed or Refractory Multiple Myeloma (RRMM), High-Risk Cytogenetics.

19 novembre 2024  | Publications

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

https://ashpublications.org/blood/article/142/Supplement%201/6724/505116/Ixazomib-Pomalidomide-and-Dexamethasone-IxPd-in